WW International (WW) announced access to Novo Nordisk’s (NVO) newly FDA approved oral formulation of Wegovy through its integrated GLP-1 platform. WW said: “The addition of a once-daily Wegovy pill expands access to GLP-1 treatment and reinforces Weight Watchers’ leadership in delivering comprehensive care models that help people succeed on medication in real life by pairing medical therapy with evidence-based behavior change and ongoing support.”
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WW:
- Balanced View on WW: Seasonal Upside and New Program Optionality Tempered by Execution Risk Supporting Hold Rating
- WW introduces fully integrated GLP-1 platform
- Novo launches introductory self-pay offer for Wegovy, Ozempic for $199 per month
- WW International’s Earnings Call: Balancing Growth and Challenges
- WW price target lowered to $38 from $41 at Morgan Stanley